AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26845191
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (pemetrexed 500 mg/m(2) every 3 weeks and cisplatin 75 mg/m(2) every 3 weeks)
Trial: 20231678
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (paclitaxel 225 mg/m(2) and carboplatin AUC 6) followed by surgery
Trial: 16438075
Drug: Subcutaneous closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous closure with 2/0 polyglactin sutures (Group-I)
Trial: 16438075
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous closure (Group-II)
Trial: 6820918
Drug: TCUK and
RxNorm normalized name: TCUK
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCUK and UUK (combined with anti-cancer agents)
Trial: 29909433
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (100, 200, or 400 µg)
Trial: 29909433
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl citrate IV 50 µg
Trial: 27304975
Drug: Bethanechol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol 150 mg
Trial: 27304975
Drug: Bethanechol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (all doses)
Trial: 12622859
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (verum) used twice daily for 3 weeks
Trial: 12622859
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel used twice daily for 3 weeks
Trial: 10638906
Drug: SGB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGB with 7 ml of 1% lidocaine
Trial: 8867248
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at 3 g/kg and higher
Trial: 8867248
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid (SA) at 15 g/kg
Trial: 8867248
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at 15 g/kg and salicylic acid (SA) at 15 g/kg
Trial: 8867248
Drug: Commercial ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercial ibuprofen (50 g/kg)
Trial: 8867248
Drug: Benzocain creams
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzocain creams (100 g/kg)
Trial: 6125193
Drug: Pindolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (15 mg)
Trial: 30998528
Drug: Coffee intake
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee intake (150 mL, 3 times per day until discharge)
Trial: 30998528
Drug: Tea intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea intake (150 mL, 3 times per day until discharge)
Trial: 26728501
Drug: modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint-induced movement therapy (m-CIMT)
Trial: 26728501
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group (conventional therapy)
Trial: 19386949
Drug: Integrated Medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Medicines Management (IMM) program
Trial: 10975216
Drug: ANP 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP 0.025 mg x kg(‐1).min(‐1)
Trial: 10975216
Drug: ANP 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP 0.05 mg x kg(‐1) x min(‐1)
Trial: 10975216
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ANP
Trial: 1414321
Drug: SCMC-Lys (mucoregulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCMC-Lys (mucoregulatory drug)
Trial: 2865251
Drug: oral concentrate
RxNorm normalized name: pectoral concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral concentrate
Trial: 2865251
Drug: intramuscular medication
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular medication
Trial: 31660915
Drug: Integrated delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated delivery of mass drug administration (MDA) for soil-transmitted helminths (STH) and mass dog rabies vaccination (MDRV)
Trial: 26815932
Drug: Oral systemic
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral systemic antibiotics
Trial: 23257663
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injection (IVRI) 0.5 mg/0.05 ml
Trial: 16051446
Drug: Bromocriptine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (maximum dose 2.5mg po tid)
Trial: 30911301
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet released growth factor (APRGF) injection (1-2 cc)
Trial: 30232851
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus fire-needle stimulation and cupping (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day, plus fire-needle stimulation and cupping once a day for 7 days)
Trial: 30232851
Drug: Medication (Famciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Famciclovir 0.25 g three times a day, Mecobalamin 0.5 g three times a day)
Trial: 27636931
Drug: Afobazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afobazole (30 mg/day)
Trial: 27636931
Drug: Diazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (30 mg/day)
Trial: 20064680
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of mixed nuts daily for 12 weeks
Trial: 17938984
Drug: Raloxifene (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (after open-label treatment)
Trial: 30467695
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after open-label treatment)
Trial: 19425461
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy plus physical therapy
Trial: 15040936
Drug: Recombinant OprF-OprI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant OprF-OprI vaccine (intramuscular injection)
Trial: 15040936
Drug: Recombinant OprF-OprI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant OprF-OprI vaccine (intranasal application)
Trial: 8214656
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of bupivacaine (0.25%; 50 mg) intra‐articularly (IA) (Group 1)
Trial: 8214656
Drug: Continuous three‐in‐one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous three‐in‐one lumbar plexus block using a catheter to administer 0.25 ml/kg of bupivacaine (0.25%; single‐shot) plus continuous pump infusion of the same drug (0.03 ml.kg‐1 x h‐1 of 0.25% bupivacaine for 24 h) (Group 2)
Trial: 8214656
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of morphine with 20 ml of saline IA (Group 3)
Trial: 3735103
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dothiepin hydrochloride
Trial: 3735103
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dothiepin hydrochloride
Trial: 3735103
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg dothiepin hydrochloride
Trial: 22253054
Drug: DISE CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISE CPAP titration
Trial: 19686304
Drug: School-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based intervention promoting sun protection and hat use; specific dosage and duration not applicable as this is baseline data before intervention.
Trial: 12466733
Drug: Climodien (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climodien (2 mg estradiol and 2 mg dienogest)
Trial: 12466733
Drug: Kliogest (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kliogest (2 mg estradiol and 1 mg norethisterone acetate)
Trial: 2183633
Drug: Oral S-adenosylmethionine
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral S-adenosylmethionine
Trial: 6445607
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg ipratropium bromide
Trial: 6445607
Drug: 80 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 μg ipratropium bromide
Trial: 6445607
Drug: 120 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 μg ipratropium bromide
Trial: 25247950
Drug: Nonlinear blended
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlinear blended images at a 25% reduced dose
Trial: 25247950
Drug: Nonlinear blended
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlinear blended images at a 50% reduced dose
Trial: 25247950
Drug: Simulated 120-kVp
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated 120-kVp linear blended images at a full dose
Trial: 10886086
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses (125, 250, 500 microg)
Trial: 26950553
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg quetiapine IR
Trial: 18608021
Drug: Anterior ultrasonography-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior ultrasonography-guided contrast injections
Trial: 18608021
Drug: Posterior ultrasonography-guided
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior ultrasonography-guided contrast injections
Trial: 16080637
Drug: Subcutaneous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous lateral internal sphincterotomy using radiofrequency bistoury (Group A)
Trial: 8026448
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg at 01:30 and 07:30
Trial: 8026448
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prophylactic nap and caffeine
Trial: 2685288
Drug: Mild analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild analgesics
Trial: 2685288
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and ibuprofen
Trial: 2685288
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or acetaminophen
Trial: 24299975
Drug: Drotaverine hydrochloride
RxNorm normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine hydrochloride (40mg) given at the start of the active phase of labor, repeated every 2 hours (maximum 3 doses)
Trial: 18807576
Drug: Losartan-hydrochlorothiazide film-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan-hydrochlorothiazide film-coated tablet formulation
Trial: 18807576
Drug: Hydrochlorothiazide film-coated
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide film-coated tablet formulation
Trial: 16204712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of (18)F‐FDG PET and APOE genotype
Trial: 10207659
Drug: Citalopram (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20‐80 mg/day)
Trial: 8597527
Drug: Flesinoxan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flesinoxan (1 mg, IV)
Trial: 6123363
Drug: Beta-blockers (late
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (late intervention)
Trial: 6123363
Drug: Beta-blockers (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (early intervention)
Trial: 27444046
Drug: Intact oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact oxycodone 40 mg, intact OxyContin® 40 and 80 mg, crushed OxyContin® 40 mg, and placebo (Cohort 1)
Trial: 27444046
Drug: Intact oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact oxycodone 20, 40, and 80 mg and placebo (Cohort 2)
Trial: 26916685
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 1-3 times daily
Trial: 26916685
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart 3 times daily + insulin detemir once daily
Trial: 26916685
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir alone once daily
Trial: 25066329
Drug: Optimised standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised standard treatment (control group)
Trial: 22314121
Drug: nano-formulated diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano-formulated diclofenac 35 mg
Trial: 22314121
Drug: nano-formulated diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nano-formulated diclofenac 18 mg
Trial: 23043637
Drug: celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 400 mg
Trial: 15133754
Drug: Glipizide GITS
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide GITS AM (5-20 mg)
Trial: 15133754
Drug: Glipizide GITS
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glipizide GITS PM (5-20 mg)
Trial: 15133754
Drug: Glibenclamide (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5-20 mg)
Trial: 12866726
Drug: Preemptive analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia (100 mg iv tramadol before induction of anesthesia)
Trial: 12866726
Drug: Preventive analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive analgesia (100 mg iv tramadol immediately after peritoneal closure)
Trial: 12866726
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 mg iv tramadol immediately after operation)
Trial: 7732668
Drug: Cotton-boll pectin
RxNorm normalized name: Cotton
DrugBank: Cotton (DB10707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton-boll pectin (1 g per 100 ml of infant milk or food, 3 times a day for 45-60 days)
Trial: 28711582
Drug: SM04690 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM04690 0.03 mg
Trial: 28711582
Drug: SM04690 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM04690 0.07 mg
Trial: 28711582
Drug: SM04690 0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM04690 0.23 mg
Trial: 23357844
Drug: Clodronate 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 200 mg/lidocaine 1% (i.m.) given twice monthly
Trial: 23357844
Drug: Clodronate 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 100 mg/lidocaine 1% (i.m.) given weekly
Trial: 19779464
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (various classes)
Trial: 3347325
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide (HCT)
Trial: 16450155
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydrochlorothiazide (HCT)
Trial: 10368203
Drug: MUSE (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MUSE (1 mg)
Trial: 1503326
Drug: Low-molecular-weight heparinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparinoid (ORG 10172), 750 anti-factor Xa units twice daily
Trial: 1503326
Drug: Unfractionated heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin, 5000 units subcutaneously twice daily
Trial: 30424980
Drug: mHELP protocols
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mHELP protocols (early mobilization, oral and nutritional assistance, and orienting communication) administered daily with usual care by a trained nurse until hospital discharge
Trial: 30658375
Drug: 3% oxalic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% oxalic acid/potassium salt solution (Super Seal Desensitizer)
Trial: 18196225
Drug: Fingolimod (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (5 mg single dose) + Atenolol (50 mg once daily for 5 days)
Trial: 18196225
Drug: Fingolimod (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (5 mg single dose) + Diltiazem (240 mg once daily for 5 days)
Trial: 10962136
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 200 mg/day for 10 days/month
Trial: 8664131
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly regimen of cisplatin 60 mg m‐2 i.v. on day 1 and etoposide 120 mg m‐2 i.v. on day 1 and 100 mg b.d. orally on days 2 and 3 alternating with cyclophosphamide 600 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v. and vincristine 2 mg i.v. all on day 1 for a maximum of six courses (3 weekly)
Trial: 8664131
Drug: 10/11 day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/11 day regimen with the same drugs but with each course consisting of half the 3 weekly dose given every 10 or 11 days for a maximum of 12 courses
Trial: 8664131
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of life measured using a daily diary card (DDC)
Trial: 1839902
Drug: Chlorthalidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (mean dose 25 mg/day)
Trial: 1839902
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean dose 200 mg/day)
Trial: 1839902
Drug: Chlorthalidone/Metoprolol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone/Metoprolol combination (logroton)
Trial: 27623757
Drug: L-arginine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6 g)
Trial: 24418244
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g cornstarch)
Trial: 16000612
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy with two cycles of carboplatin and paclitaxel
Trial: 12800728
Drug: Lactose-containing milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-containing milk (240 mL daily for 14 days)
Trial: 12800728
Drug: Lactose-hydrolyzed milk
RxNorm normalized name: MILK PROTEIN,HYDROLYZED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-hydrolyzed milk (240 mL daily for 14 days)
Trial: 10483329
Drug: Naftidrofuryl (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (200 mg three times daily)
Trial: 8354803
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy with either streptokinase or recombinant tissue-type plasminogen activator within 7 hours of symptom onset (mean 4.8 hours)
Trial: 1899433
Drug: Intravenous thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic therapy
Trial: 26122891
Drug: Twice-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sessions at the start of CBT
Trial: 26122891
Drug: Twice-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sessions at the start of IPT
Trial: 26122891
Drug: Once-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly sessions at the start of CBT
Trial: 26122891
Drug: Once-weekly sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly sessions at the start of IPT
Trial: 22088518
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 - 120 mg
Trial: 15259448
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibition (abciximab) in addition to dalteparin (subcutaneous)